SOLID TUMOR

This study tests a new drug called HRS-8364 in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose and check if the drug shrinks tumors. About 282 adults aged 18-75 will take part.

This study tests a drug called KN035 in people with advanced solid tumors that have a specific genetic feature (dMMR or MSI-H). These tumors often don't respond well to standard treatments. The goal is to see if KN035 can shrink tumors and control the disease. About 200 participa…

This early-stage study tests a new drug called JBZ-001 in about 25 adults with advanced solid tumors or certain blood cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink or control t…

This early-phase trial tests a new drug called BB-1709 in about 300 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the …

This early-phase study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. AGX101 is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find the safest dose and to check for sid…

This study tests a radioactive drug called Lu-177 edotreotide in children aged 2 to 17 with tumors that have a specific marker (SSTR). The goal is to find the right dose and check if it is safe. About 20 children whose tumors came back or did not respond to prior treatment will t…

This early-phase study tests a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and understand side effects. About 493 adults with certain cancers like colorectal, lung, or pancre…

This study tests a new drug called HY0001a in 261 adults with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study is in two parts: first to check safety and dosing, then to measure h…

This early-phase study tests a new drug called STP938 in about 70 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and how the body processes it. A special focus is on ovarian cancers missing a specifi…

This early-phase study tests a new drug called GNC-077 in 20 people with advanced breast cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have a tumor that can be measu…

This early-phase study tests a new drug called DR30206 in people with advanced or metastatic solid tumors who have run out of standard options. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 216 adults aged 18 to 75 will…

This study tests an experimental drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants will be monitored for sid…

This early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find the safest dose and check for side effects. Researchers will also watch for any signs that the dru…

This study tests a new treatment called Enhanced ALPP CAR-T cells for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target a protein called ALPP found on some tumor cells. The…

This early-phase study tests a new drug called GTB-5550 in people with advanced solid tumors that no longer respond to standard treatments. The drug is designed to connect natural killer cells to cancer cells, helping the immune system attack the tumor. About 175 adults aged 18 a…

This early-phase study tests a new drug called SHR-A1811(sc) given as a shot under the skin for people with solid tumors. The main goals are to see how the drug moves through the body, if it is safe, and if it helps shrink tumors. About 107 adults with advanced solid tumors will …

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This study follows up to 100 people with cancers like melanoma, lung cancer, or rare tumors who are already benefiting from treatment with dabrafenib and/or trametinib. The goal is to monitor long-term safety and side effects while patients continue their medication. Participants…

This early-stage study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. The goal is to find safe doses and see if th…

This study looks at how well umbilical cord blood stem cells from unrelated donors help patients with serious blood cancers, immune problems, or genetic disorders. About 30 people will receive a transplant to see how quickly their blood cells recover and how often the transplant …

This study tests an experimental drug called SMP-3124LP in 120 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is safety and…

This study tests a drug called pembrolizumab in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, come back, or not responded to treatment. The drug helps the immune system fight cancer. The goal is to see if it can shrink or el…

This study tests an experimental drug, 177Lu-FAP-2286, that delivers radiation directly to cancer cells in people with advanced solid tumors. The drug targets a protein called FAP found on cells surrounding many tumor types. The trial has two parts: first, finding a safe dose, th…

This early-phase study tests a new drug called GNC-077 in about 20 people with advanced lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must have a tumor that can …

This early-stage study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. …

This study tests an experimental drug called SAR445877 in about 542 adults with advanced solid tumors that have spread or can't be removed. The goal is to find safe doses and see if the drug, given alone or with other cancer treatments, can shrink tumors. The trial has two parts:…

This early-phase study tests an experimental drug called PT0253 in adults with advanced solid tumors that have a specific genetic change (KRAS G12D mutation). The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 115 participa…

This study tests two experimental drugs (LB1410 and LB4330) given together to people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About 194 adults will take…

This early-phase trial tests a new drug called IBI3026 in 300 adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and check for side effects. Researchers will also monitor how the drug affects tumor growth and…

This early-phase study tests whether specially trained donor immune cells (TAA-T cells) are safe for children with high-risk solid tumors like neuroblastoma, sarcoma, or Wilms tumor that have come back or not responded to standard treatments. Up to 36 participants will receive ce…

This early-stage trial tests an injection made from a modified bacteria (CMTS1215) to treat solid tumors. It is for up to 20 adults whose cancer has not responded to standard therapies. The goal is to see if the bacteria can shrink tumors and to check for side effects.

This study is the first time AT03-65 is being tested in humans. It aims to find a safe dose and check for side effects in 83 adults with advanced solid tumors that have not responded to standard treatments. The drug is given to see if it can help control the disease, but particip…

This study is testing a new combination of two drugs (AL8326 and toripalimab) in people with advanced solid tumors that have stopped responding to standard therapy or have no other treatment options. The trial has two parts: first, finding the safest and most effective dose, and …

This early-phase trial tests a new treatment for people with advanced solid tumors that have not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) designed to find and attack cancer cells that carry a protein called CLDN6. Some part…

This early-phase study tests a modified virus called VRT106 that is injected directly into tumors to see if it is safe and can shrink cancers. About 30 adults with advanced solid tumors that have not responded to standard treatments will receive the virus. The main goal is to fin…

This early-phase study tests a new drug called XB628 in about 75 people with advanced solid tumors that have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to find a safe dos…

This early-phase study tests a new drug, SB17170, in about 50 adults with advanced solid tumors that no longer respond to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and lo…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The goal is to control the disease in people whose cancer has not responded to standard therapies. Up to 100 participants aged 1 …

This early-phase study tests a new drug called HYP-6589 in people with advanced solid tumors (including a type of lung cancer). The study has two parts: first, finding a safe dose of HYP-6589 alone; second, testing it combined with other targeted drugs. About 115 adults with tumo…

This study tests an experimental drug called MCLA-129 in people with advanced solid tumors, including lung, head and neck, and colorectal cancers that have stopped responding to standard treatments. The drug is a bispecific antibody designed to target two cancer-related proteins …

This study is testing an experimental radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The drug is designed to deliver radiation directly to tumors. The main goals ar…

This early-phase study tests a new drug called BL-B16D1 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 21 adults aged 18 to 75 will take par…

This study tests a new drug called YH42946 in people with advanced solid tumors (including lung cancer) that have certain gene changes (HER2 or EGFR). The main goals are to check safety, how the drug moves through the body, and whether it shrinks tumors. About 161 participants wh…

This study tests an experimental drug called TL118 in adults with advanced solid tumors that have a specific genetic change (NTRK gene fusion). The goal is to see if TL118 can shrink tumors or stop them from growing. About 60 participants will receive the drug, and researchers wi…

This study tests a drug called selinexor in children and young adults whose Wilms tumor, rhabdoid tumor, or other solid tumors have come back or not responded to treatment. The goal is to see if the drug can shrink tumors. About 45 participants will take selinexor pills, and doct…

This early-phase trial tests a new drug called TH9619 in 43 adults with advanced solid tumors (colorectal, head and neck, lung, or stomach cancer) that have not responded to prior treatment. The main goal is to find a safe dose and check for side effects. Researchers will also wa…

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment involves two injections given directly into the tumor, one after the other. The goal is to see if the combination is safe and can help control the d…

This study tests a new drug called JK06, which is designed to seek out and attack cancer cells while sparing healthy ones. It is for people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the safest dose and see if the drug …

This early-stage trial tests an experimental pill, GIM-531, in people with advanced solid tumors (including stage IV melanoma) that have stopped responding to standard treatments. The drug works by blocking certain immune cells that protect tumors, potentially helping the body fi…

This early-phase study tests a new drug called PT0511 in adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works alone or w…

This early-stage trial tests a new drug called DXP-106 in about 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug works alone or with chemotherapy. Participants receive the drug by IV, and t…

This study tests a new drug called SHR-7367 combined with other cancer treatments for people with advanced solid tumors. The goal is to find the safest dose and see if the combination shrinks tumors. About 100 adults aged 18-75 with measurable tumors and good organ function can j…

This early-phase study tests the safety of combining two drugs, BMS-986504 and olaparib, in people with advanced solid tumors that have lost a gene called MTAP. The goal is to find safe doses and understand side effects. About 36 adults whose cancer has not responded to standard …

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help children whose solid tumors have come back or not responded to treatment. About 23 children with relapsed or refractory solid tumors (including rhabdomyosarcoma) will receive the…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study tests a new drug called NUC-7738 in people with advanced solid tumours or lymphoma that have not responded to other treatments. The goal is to find the safest dose and see if it can shrink tumours, either alone or combined with another drug (pembrolizumab). About 135 a…

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in 52 adults with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. Parti…

This study tests a drug called Envafolimab in people with advanced solid tumors that have a high number of genetic mutations (TMB-H). The goal is to see how well the drug shrinks tumors and to find the best way to measure mutation levels. About 126 adults who have tried at least …

This early-phase study tests a new drug called CBP-1019 combined with standard chemotherapy and other treatments for people with advanced solid tumors that have stopped responding to prior therapy. The goal is to find safe doses and see if the combinations can shrink tumors or sl…

This study tests an experimental pill called JAB-21822 (Glecirasib) in people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation and have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and con…

This early-stage study tests a new drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 330 partici…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) in people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various cancers, inclu…

This study is testing a drug called toripalimab, which helps the immune system fight cancer. It is for people with advanced solid tumors that have specific gene changes (POLE or POLD-1) but not high microsatellite instability. The goal is to see if the drug can shrink tumors and …

This study tests whether giving the immunotherapy drug TSR-042 first, followed by standard chemoradiotherapy and surgery, can shrink or eliminate advanced solid tumors that have a specific genetic feature called mismatch repair deficiency (dMMR). About 212 adults with locally adv…

This study is testing a new drug, IPG1094, in about 60 adults with advanced solid tumors that cannot be cured by surgery. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, finding the right dose, then testing that dose in more …

This early-stage study tests an oral probiotic (R-5780) taken alongside a standard immunotherapy drug (PD-1 inhibitor) in adults with advanced solid tumors like melanoma. The main goal is to check safety and side effects. About 33 participants will be enrolled to see if this comb…

This early-phase study tests a new drug called BL-M17D1 in about 20 people with advanced HER2-positive or low-HER2 cancers of the digestive tract (esophagus, stomach, pancreas, colon) and other solid tumors. The main goals are to check safety, find the best dose, and see if the d…

This study tests a new drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults with can…

This early-phase trial tests the safety of a new drug called NP-101 in about 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. This is a first step to see if NP-101 might hel…

This study tests a new treatment called QH101 for people with blood cancers or solid tumors that have not responded to standard therapy. QH101 uses specially engineered immune cells to better recognize and kill cancer cells while avoiding burnout. The trial aims to see if it is s…

This study tests a new drug called MORAb-202 for people with certain solid tumors, including ovarian, endometrial, lung, and breast cancers. The drug works by targeting a protein on cancer cells to deliver chemotherapy directly. The trial aims to find the safest and most effectiv…

This early-phase study tests an experimental drug called BGB-26808, either alone or combined with an immunotherapy (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe and recommended dose. About 217 …

This early-phase study tests a new drug called BL-M24D1 in 33 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried other tr…

This early-phase study tests a new drug called BL-B16D1 in people with head and neck cancer or other solid tumors that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 21 adults who have not resp…

This early-stage study tests a new drug called BHV-1530 in about 95 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug …

This study tests a new drug, BHV-1510, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, finding the safest dose, and second, checking if the drug shrinks tumors when used alone or with another cancer drug (cemip…

This study tests a new drug called JZP815 in people with advanced or spreading solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to find a safe dose and see if the drug can shrink tumors. About 332 adults who have tried all other standard tre…

This study tests whether giving children with high-risk solid tumors a daily combination of sirolimus and low-dose chemotherapy for 12 months after standard treatment can keep the cancer from coming back. About 55 participants aged 1 to 30 years will take part. The goal is to see…

This early-stage study tests a new drug called GNC-039 in about 60 people with brain tumors (glioma) or other solid cancers that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must have tr…

This study tests a new drug called HRS-4508 in 120 people with advanced non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to see if the drug shrinks tumors and to check for side effects. Participants must be between 18 and 80 years …

This early-phase study tests a new drug called BL-M17D1 in about 20 adults with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants…

This early-stage trial tests an experimental drug called IMGS-001 in people with advanced solid tumors that have come back or stopped responding to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in specific cancer types like ovari…

This early-stage study tests the safety of combining two drugs, NEROFE and doxorubicin, in people with advanced solid tumors that have a specific genetic change (KRAS mutation) and a protein called ST2. The goal is to find the best dose and schedule. About 24 adults whose cancer …

This early-phase study tests a new drug, SON-DP, in about 96 adults with advanced solid tumors, including liver and gastric cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. Participants must have measurab…

This study tests two drugs, VS-6766 and defactinib, in people with certain gynecological cancers that have come back. The goal is to see if the combination can shrink tumors and how safe it is. About 55 adults with specific gene mutations (RAS, BRAF, or NF1) will take part.

This study tests an experimental drug called ZGGS34 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, then testing how well ZGGS34 works alone or with chemotherapy in tumors that have a specif…

This early-stage study tests a new drug called OCT-598 in about 51 adults with advanced solid tumors (breast, lung, prostate, head/neck, or stomach cancer). The main goals are to check safety, find the best dose, and see how the drug works alone or with standard treatments. Parti…

This study tests a new drug called BL-B01D1 in 38 adults with advanced gynecological or other solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. Researchers will also monitor side effects clos…

This study tests a new oral drug, TNG456, in people with advanced solid tumors that lack a gene called MTAP. The drug aims to slow or stop cancer growth by blocking a protein these tumors rely on. The trial has two parts: first finding the safest dose, then testing how well it wo…

This early-stage study is testing a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with solid tumors that have returned or not responded to treatment. The main goal is to find a safe dose and check for side effects. The study is…

This study tests two experimental drugs, 7MW3711 and JS207, given together (sometimes with chemo) to people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the combination can shrink tum…

This study tests whether adding bevacizumab to standard chemotherapy before surgery can improve outcomes for people with early or locally advanced HER2-negative breast cancer. About 75 adults will receive the combination, and researchers will measure how many achieve a complete r…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better attack cancer. The trial enrolls 18 adults with advanced solid tumors (including breast, lung, and gastrointestinal cancers) who have not re…

This study tests a new daily pill, INX-315, in 150 people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study includes three parts: testing the…

This early-stage study tests a new drug called OBT076 in people with advanced solid tumors that have come back or spread. OBT076 is designed to find and attack cancer cells that have a specific protein (CD205) on their surface. The main goals are to find a safe dose and check for…

This early-phase study tests a new drug, ASP3082, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The study aims to find safe doses of ASP3082, given alone or with another drug (cetuximab). About 681 participants will receive the treatme…

This study is for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial tests a new drug, GDC-7035, given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tum…

This early-phase study tests a new drug called BL-M08D1 in about 22 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the …

This early-phase study tests a new treatment approach for people with large solid tumors that have not responded to standard therapy. The treatment combines low-dose radiation, precise high-dose radiation, and an immunotherapy drug called tislelizumab. The main goal is to check s…

This study tests a new oral drug, IPN01194, in adults with advanced solid tumors (melanoma, colorectal, pancreatic, or head and neck cancers) that have not responded to standard treatments. The goal is to find the right dose and check if the drug is safe and can shrink tumors. Ab…

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to activate the immune system, followed by an infusion…

This early-stage trial tests a personalized vaccine made from a patient's own tumor, designed to help the immune system attack cancer. It is for people with advanced solid tumors who have tried other treatments. The main goal is to check safety and see if the vaccine can slow can…

This study tests a new drug, ASP5834, for people with advanced solid tumors that have certain changes in the KRAS gene. The drug is given alone or with another drug (panitumumab) for colorectal cancer. The main goals are to find a safe dose and check for side effects. About 364 a…

This early-stage trial tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their gro…

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and shrinks tu…

This study tests an experimental drug called TRK-950, alone or with another drug (nivolumab), in people with advanced solid tumors or melanoma that have not responded to standard treatments. The goal is to check safety, find the right dose, and see if the drug can shrink tumors. …

This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) w…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This early-phase study tests a new drug called BL-M24D1 in 16 people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must be 18 or older and have t…

This early-stage study tests an experimental drug called LB1410 in people with advanced solid tumors or lymphoma that hasn't responded to standard treatments. The drug is a bispecific antibody designed to target two immune checkpoints (PD-1 and TIM-3) to help the immune system fi…

This early-phase study tests a new approach called peptide alarm therapy (PAT) given as an injection directly into tumors, along with a standard immunotherapy drug, for people with advanced solid tumors that have stopped responding to at least one prior treatment. The goal is to …

This early-phase study tests a new drug called BL-B01D1 in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 36 adults aged 18 to 75 will take part.

This study tests a new drug called SHR-9839 combined with other anti-tumor treatments for people with advanced solid tumors. The goal is to see if the combination is safe and helps shrink or control tumors. About 70 adults aged 18-70 with measurable tumors and good performance st…

This early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…

This early-phase study tests a new drug called BL-B16D1 in 21 adults with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participant…

This early-phase study tests a new drug called BM230 in people with advanced solid tumors that are linked to HER2. The goal is to find a safe dose and check for side effects. About 123 participants will take part, first in a dose-finding stage, then in a stage that looks more clo…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain types of breast cancer, head and neck cancer, or …

This study tests a new drug called CUSP06 for people with ovarian cancer or other solid tumors that have stopped responding to standard treatments. The drug works like a guided missile, targeting a protein on cancer cells to deliver a powerful toxin directly. The main goals are t…

This study tests a new drug called JYP0015 in adults with advanced solid tumors that have a specific genetic change called RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people with pancreatic, lung, or colorectal cancer will take part.

This study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if it shrinks tumors. Some lymphoma patients will also get the drug combined with rituximab. Participants take SB-4826…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors (including some lung cancers) that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants …

This study tests a combination of two drugs (BL-B01D1 and a PD-1 antibody) in adults with advanced or spreading non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors. The goal is to see if the combo can shrink tumors and control the disease. About 570 participa…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study is testing a new imaging agent called [68Ga]Ga-THP-PDL1-3 that lights up a protein (PD-L1) on cancer cells during a PET/CT scan. The goal is to see where and how much PD-L1 is present in tumors, which could help doctors choose the right treatments and monitor changes o…

This study tests a new PET imaging method to detect a protein called CLDN18.2 in solid tumors. The goal is to identify patients who might benefit from treatments that target this protein. About 15 adults with solid tumors will receive a special tracer and then have a PET/CT scan.…

This study is testing a new type of PET scan that targets a protein called Trop2, found on many solid tumors. The goal is to see if this scan can find and stage cancers like bladder, lung, liver, and ovarian cancer better than current methods. About 400 adults with confirmed or s…

This study looks at whether medical hypnosis, combined with relaxing music, can reduce anxiety in cancer patients who are moderately to very anxious during their radiation treatments. About 45 adults with solid tumors will be randomly assigned to either listen to music alone or l…

This pilot study tests if brodalumab, a drug approved for autoimmune diseases, can safely reduce severe side effects caused by cancer immunotherapy. About 11 adults with various solid tumors who have immune-related side effects will receive brodalumab. The goal is to see if it lo…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, have trouble sleeping, or are very tired. The program is delivered through telehealth (video or phone calls) and includes up to 8 sessions. Resear…

This study is testing a culturally tailored counseling program for Latinos with advanced cancer. The goal is to improve their quality of life and emotional well-being. About 285 adults who speak Spanish or both Spanish and English will take part. Researchers will measure changes …

This study tests whether a one-day hospital visit with medical, psychological, and social support after finishing cancer treatment can improve quality of life for teens and young adults (ages 15-25) with solid tumors or lymphoma. 214 participants will be randomly assigned to rece…

This study tests whether a program of targeted exercise and psychological support before cancer treatment (surgery or radiation) can improve physical and mental recovery in patients with solid tumors like breast cancer. About 125 participants will either receive this prehabilitat…

This study aims to adapt a counseling approach called Meaning Centered Psychotherapy to better support Latinos with advanced cancer. Researchers will work with 190 participants to see if the culturally tailored program improves spiritual well-being and eases anxiety and depressio…

This study tests a program where specially trained nurses start conversations about palliative care early after a child's cancer diagnosis. The goal is to see if this improves the child's quality of life and reduces symptoms. About 120 children with solid tumors or blood cancers …

This study is testing a new tool that predicts whether immunotherapy will work for people with melanoma and other skin cancers. Researchers will collect tumor tissue, blood, and stool samples from 1,000 participants and compare the tool's predictions to actual treatment outcomes.…

This study tests whether cancer patients getting chemotherapy can use an Apple Watch and a special iPhone app to track their health from home. About 100 adults with solid tumors or blood cancers will wear the watch during waking hours for at least 4 months. The goal is to see if …

This study looks at the genetic makeup of tumors from 5,500 people with solid cancers. The goal is to use this information to match each person with the most suitable clinical trial or treatment. Participants must have a confirmed solid tumor and be able to provide a tissue sampl…

This study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk together about stem cell transplant or cellular therapy decisions. About 60 youth and their parents will try the tool and report how easy and helpfu…

This study is creating a registry of very rare solid tumors in people aged 1 month to 39 years. Researchers will collect medical records, tumor samples, and survey answers from participants over 5 years. The goal is to gather enough information to better understand these rare can…

This study looks at how the body's immune cells react to a new type of cancer vaccine called a neoantigen vaccine. Researchers will collect blood samples from 24 people with solid tumors or healthy volunteers to study immune responses. The goal is to learn how to better grow and …

This study aims to safely collect health information from wearable devices (like smartwatches) from over 3,600 people with solid tumors. Researchers will use this data to explore how things like heart rate and activity levels relate to cancer diagnosis, treatment response, and ri…

This study collects biological samples and health information from up to 10,000 people with rare solid tumors or a family history of them. The goal is to learn how these tumors develop and change over time. Participants provide saliva, blood, or tumor tissue and answer yearly hea…

This study is adapting a program called CONVO for Spanish-speaking Latinx cancer patients. In the program, nurses and patients talk about the patient's personal values during routine cancer care. The goal is to make sure care aligns with what matters most to each patient.

This study looks at whether a special dye called Indocyanine Green (ICG) can help surgeons find lymph nodes that might contain cancer during surgery for children with solid tumors in the belly. About 25 children under 21 with Wilms tumor or a type of muscle cancer will get the dy…

This study follows 940 adults with solid tumors who are starting immunotherapy. Researchers collect blood and tissue samples before and during treatment to track side effects, especially those affecting the brain and nerves. The goal is to find early warning signs and better unde…

This study looks at sleep issues in adults who survived childhood cancer, focusing on three groups: those treated for ALL, brain tumors, or solid tumors. Researchers will use questionnaires and home sleep monitors to measure insomnia, sleep quality, and daytime sleepiness. The go…

This early-phase study tests whether a new radioactive tracer can help doctors see tumors on PET/CT scans. About 32 adults with different solid tumors will receive a single injection of the tracer. The goal is to understand where the tracer goes in the body, how it is cleared, an…

This study aims to find genetic changes in the tumors of 10,000 adults with advanced solid tumors or blood cancers. Researchers will use advanced DNA testing to look for 'actionable' alterations that could be targeted by existing drugs. Patients with a matching alteration may the…

This early-phase study tests whether artificial intelligence can help doctors choose and dose the right combination of cancer drugs for each person with a solid tumor (like breast or gastrointestinal cancer). Researchers will use a patient's own tumor sample in the lab to find th…

This study tests whether a green dye called Indocyanine Green (ICG) can help surgeons see tumors during surgery in children and teens with solid tumors. About 230 participants will receive the dye before surgery, and special cameras will detect the glow to guide removal. The goal…

This study looks at whether a blood test (liquid biopsy) can find genetic changes in tumors to help doctors pick the best treatment. About 150 people with solid cancers will give blood samples before and during treatment. The goal is to see if these tests can guide therapy decisi…

This study follows 400 men with solid tumors to understand how cancer care impacts their ability to work and their overall well-being. It focuses on low-income and Latino men, who often face extra challenges. Researchers will track employment hours, mental health, and financial s…

This study looks at 50 adults with advanced solid tumors that no longer respond to standard treatments. Researchers will use genetic tests to match patients with experimental or off-label therapies, then track how well the tumors shrink and how patients feel. The goal is to creat…

This study follows 100 children and young adults who have received CAR T-cell therapy to learn about short- and long-term side effects. Researchers will track how often patients get infections, have delays in blood cell recovery, or experience nerve damage. The goal is to better …